IL327342A - Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer - Google Patents

Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer

Info

Publication number
IL327342A
IL327342A IL327342A IL32734226A IL327342A IL 327342 A IL327342 A IL 327342A IL 327342 A IL327342 A IL 327342A IL 32734226 A IL32734226 A IL 32734226A IL 327342 A IL327342 A IL 327342A
Authority
IL
Israel
Prior art keywords
claudin
antibodies
cancer
treatment
combination
Prior art date
Application number
IL327342A
Other languages
Hebrew (he)
Original Assignee
I Mab Biopharma Us Ltd
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd, Abl Bio Inc filed Critical I Mab Biopharma Us Ltd
Publication of IL327342A publication Critical patent/IL327342A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL327342A 2023-09-27 2024-09-27 Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer IL327342A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023122092 2023-09-27
PCT/CN2024/121653 WO2025067400A1 (en) 2023-09-27 2024-09-27 Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer

Publications (1)

Publication Number Publication Date
IL327342A true IL327342A (en) 2026-05-01

Family

ID=95204334

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327342A IL327342A (en) 2023-09-27 2024-09-27 Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer

Country Status (3)

Country Link
AU (1) AU2024351740A1 (en)
IL (1) IL327342A (en)
WO (1) WO2025067400A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166265B (en) 2019-08-12 2024-06-04 天境生物科技(上海)有限公司 Bispecific antibody against claudin 18.2 and anti-4-1 BB and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116178555B (en) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 Anti-claudin 18.2 antibodies and uses thereof
CN111518214B (en) * 2019-02-03 2023-09-22 上海健信生物医药科技有限公司 Bispecific antibodies targeting CLDN18.2 and preparation methods and applications thereof
EP3826612A4 (en) * 2018-07-25 2022-09-14 Accurus Biosciences, Inc. NOVEL MONOCLONAL ANTIBODIES SPECIFIC TO CLDN 18.2 AND THEIR METHODS OF USE
CN113166265B (en) * 2019-08-12 2024-06-04 天境生物科技(上海)有限公司 Bispecific antibody against claudin 18.2 and anti-4-1 BB and uses thereof
CN120077072A (en) * 2022-11-29 2025-05-30 江苏恒瑞医药股份有限公司 CLDN18.2/4-1BB binding protein and medical application thereof

Also Published As

Publication number Publication date
AU2024351740A1 (en) 2026-04-16
WO2025067400A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
MX2024012131A (en) Pharmaceutical composition, use thereof, and method for treating cancer
HUS1200022I1 (en) Methods of treatement using ctla-4 antibodies
WO2004032857A8 (en) Antibody therapy
TNSN05300A1 (en) Treatment with anti-vegf antibodies
IL184617A0 (en) Dr5 antibodies and uses thereof
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
MXPA03010121A (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
PH12022551960A1 (en) Antibodies binding to b7h4
MX2022009091A (en) Antibodies for use in therapy.
IL314346A (en) Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
IL299334A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
PH12022551021A1 (en) Sequential anti-cd19 therapy
UA87877C2 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
GB0008172D0 (en) Therapy
IL314984A (en) Oral pclx-001 in the treatment of human cancer
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
CA3305331A1 (en) Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer
MX2023006404A (en) Antibody and taxane combination therapy.
MX2024001892A (en) A therapeutic combination comprising a t1git antagonist, a pd-1 antagonist, and a chemotherapeutic agent(s).
TW200724158A (en) Combination therapy in the treatment of cancer
AU2003229876A8 (en) Tumour associated antigens
CA3252992A1 (en) Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy
HK40114470A (en) Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy